Detalhe da pesquisa
1.
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Nature
; 558(7710): E1, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769713
2.
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Nature
; 550(7674): 128-132, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28953875
3.
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.
J Med Chem
; 60(20): 8321-8335, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926243
4.
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
J Med Chem
; 60(20): 8369-8384, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949521
5.
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.
MAbs
; 3(5): 487-94, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21814039